Importer of Controlled Substances Application: Galephar Pharmaceutical Research Inc., 49555 [2019-20412]
Download as PDF
<![CDATA[
49555
Federal Register / Vol. 84, No. 183 / Friday, September 20, 2019 / Notices
A person who is licensed as a physician,
however, is ‘‘registered’’ and exempt
from the statute’s registration fee and
application requirements. Ga. Code
Ann. § 16–13–35(g)(2) (Westlaw, current
through acts passed during the 2019
Session of the General Assembly). The
Georgia Code defines ‘‘physician’’ as ‘‘a
person licensed to practice medicine.’’
Ga. Code Ann. § 43–34–21(2) (Westlaw,
current through acts passed during the
2019 Session of the General Assembly).
Under Georgia law, ‘‘to practice
medicine’’ includes ‘‘attaching the title
‘M.D.’ . . . to one’s name, indicating
that such person is engaged in the
treatment or diagnosis of disease,
defects, or injuries to human beings.’’
Ga. Code Ann. § 43–34–21(3) (Westlaw,
current through acts passed during the
2019 Session of the General Assembly).
Here, the undisputed evidence in the
record, including Respondent’s
admission, is that Respondent currently
lacks authority to practice medicine in
Georgia. Government Motion, Exhs. 2–4;
RMRC, at 2. As already discussed, a
‘‘physician,’’ under Georgia law, is a
person licensed to practice medicine.
Further, under Georgia law, a
‘‘physician’’ is registered to dispense
controlled substances. Because
Respondent lacks authority to practice
medicine in Georgia, he is not registered
to handle controlled substances in
Georgia according to Georgia law.
Accordingly, Respondent is not eligible
to maintain a DEA registration and I will
order that Respondent’s DEA
registration be revoked.6
Order
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. BS4014332 issued to
John Yolman Salinas, M.D. Pursuant to
28 CFR 0.100(b) and the authority
vested in me by 21 U.S.C. 823(f), I
hereby deny any pending application of
John Yolman Salinas to renew or to
modify this registration, and any
pending application of John Yolman
Salinas to be registered in the state of
Georgia. This Order is effective October
21, 2019.
6 Given my findings that Respondent is registered
with the DEA in Georgia, that his Georgia medical
license is revoked, and that he lacks authority in
Georgia to dispense controlled substances, I find
that both of Respondent’s CAPs—changing his
registered address to another state or a Territory of
the United States, and ‘‘procuring a position as an
undercover physician to infiltrate pill mills and
help in the war against drugs’’—provide no basis for
me to discontinue or defer this proceeding. 21
U.S.C. 824(c)(3).
VerDate Sep<11>2014
17:13 Sep 19, 2019
Jkt 247001
Dated: September 9, 2019.
Uttam Dhillon,
Acting Administrator.
Dated: August 19, 2019.
Neil D. Doherty,
Acting Assistant Administrator.
[FR Doc. 2019–20420 Filed 9–19–19; 8:45 am]
[FR Doc. 2019–20414 Filed 9–19–19; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
[Docket No. DEA–392]
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
Importer of Controlled Substances
Application: Galephar Pharmaceutical
Research Inc.
ACTION:
ACTION:
Notice of application.
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 21, 2019. Such
persons may also file a written request
for a hearing on the application on or
before October 21, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on June 10, 2019, Galephar
Pharmaceutical Research Inc., #100 Carr
198 Industrial Park, Juncos, Puerto Rico,
00777 applied to be registered as an
importer of the following basic class of
controlled substance:
DATES:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 21, 2019. Such
persons may also file a written request
for a hearing on the application on or
before October 21, 2019.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on July 19, 2019, Fisher
Clinical Services, Inc., 700A–C Nestle
Way, Breinigsville, Pennsylvania
18031–1522 applied to be registered as
an importer of the following basic
classes of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Psilocybin .................
Methylphenidate .......
Levorphanol ..............
Noroxymorphone ......
Tapentadol ................
Drug
code
7437
1724
9220
9668
9780
Schedule
I
II
II
II
II
The company plans to import the
listed controlled substances for clinical
trials.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Controlled substance
Hydromorphone ........
Drug
code
9150
Schedule
II
The company plans to import the
listed controlled substance in finished
dosage form for analytical purpose only.
Dated: August 22, 2019.
Neil D. Doherty,
Acting Assistant Administrator.
[FR Doc. 2019–20412 Filed 9–19–19; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\20SEN1.SGM
20SEN1
]]>Agencies
[Federal Register Volume 84, Number 183 (Friday, September 20, 2019)]
[Notices]
[Page 49555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-20412]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Galephar
Pharmaceutical Research Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before October 21, 2019.
Such persons may also file a written request for a hearing on the
application on or before October 21, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on June 10, 2019, Galephar Pharmaceutical Research Inc.,
#100 Carr 198 Industrial Park, Juncos, Puerto Rico, 00777 applied to be
registered as an importer of the following basic class of controlled
substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Hydromorphone......................... 9150 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
finished dosage form for analytical purpose only.
Dated: August 22, 2019.
Neil D. Doherty,
Acting Assistant Administrator.
[FR Doc. 2019-20412 Filed 9-19-19; 8:45 am]
BILLING CODE 4410-09-P
